You are here: Industry Insights > obesity

News List

Novo Nordisk’s weight loss drug semaglutide found to improve wellbeing pharmatimes
May 14, 2021
New results from a Phase IIIa study have demonstrated that Novo Nordisk’s weight loss drug semaglutide improved physical function and wellbeing among people with obesity.
Novo Nordisk plans study of oral semaglutide in obesity pharmatimes
April 23, 2021
Novo Nordisk is planning to initiate a Phase IIIa study of oral semaglutide in obesity, the Danish pharma company announced 21st.
Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years prnasia
March 29, 2021
Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment of obesity in adolescents aged 12–17 years.
Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial prnasia
March 24, 2021
New results from the STEP phase 3a clinical trial programme demonstrated weight loss with investigational treatment of once-weekly subcutaneous semaglutide 2.4 mg versus placebo.
Boehringer Ingelheim, Gubra to validate new Peptides for obesity pharmaceutical-business-review
March 05, 2021
Boehringer Ingelheim has entered into a new research and licensing agreement with biotech company Gubra to identify and validate innovative peptides to treat obesity.
Sciwind's Investigational New Drug Approved for NASH Trial prnasia
March 01, 2021
Hangzhou Sciwind Biosciences Co., Ltd. today announced that XW003, a potential candidate for the treatment of non-alcoholic steatohepatitis (NASH), has been approved by China NMPA for clinical trial.
Novo Nordisk’s semaglutide cuts body weight in large-scale trial pharmatimes
February 24, 2021
Novo Nordisk’s glucagon-like peptide-1 (GLP-1) agonist semaglutide significantly cut body weight in a large-scale trial of adults who are overweight or obese.
February Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights europeanpharmaceuticalreview
February 19, 2021
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) began two new reviews and wrote guidance for healthcare professionals on the potential side effects of Strimvelis, Venclyxto and Zolgensma.
UK researchers find semaglutide could be a ‘game changer’ drug to fight obesity expresspharma
February 18, 2021
The drug, semaglutide, works by hijacking the body's own appetite-regulating system in the brain leading to reduced hunger and calorie intake, according to the study.
Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural therapy prnasia
November 06, 2020
Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to intensive behavioural therapy (IBT) demonstrated significantly more body weight loss compared to placebo plus IBT.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page